Want to see EDVA full AI Analyst Report?
Top Page
Endovia Health Sciences Inc
(EDVA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.41
▼(-2.86% Downside)
Action:Reiterated
Date:08/27/26
The score is primarily held down by very weak financial performance (collapsed/abnormal revenue, large ongoing losses, negative equity, and persistent cash burn). Technicals are mixed with a longer-term downtrend despite near-term stabilization, and valuation is not supportive given the negative P/E and lack of dividend. Corporate events provide some incremental upside via an early FDA veterinary regulatory milestone and incentive-focused leadership changes, but they do not outweigh the current financial stress.
Positive Factors
FDA veterinary development milestone
Opening the INAD file formally begins FDA development of CannEpil for veterinary cancer pain. This creates a regulatory pathway, supports future clinical and manufacturing work, and could establish a differentiated therapeutic opportunity if development succeeds.
Negative Factors
Severe revenue deterioration
The collapse in reported revenue indicates severe disruption to the operating business and undermines the company’s ability to support development costs. Without a sustained recovery in sales, future growth, financing capacity, and strategic execution remain highly uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA veterinary development milestone
Opening the INAD file formally begins FDA development of CannEpil for veterinary cancer pain. This creates a regulatory pathway, supports future clinical and manufacturing work, and could establish a differentiated therapeutic opportunity if development succeeds.
Read all positive factors
Endovia Health Sciences Inc (EDVA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.68M
Dividend YieldN/A
Average Volume (3M)3.65M
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue Growth-83.63%
EPS Growth65.38%
CountryUS
Employees2
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-26.79
Shares Outstanding6,412,521
10 Day Avg. Volume5,591,683
30 Day Avg. Volume3,647,912
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.10
Price to Sales (P/S)20.57
P/FCF Ratio-0.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-52.8
Revenue Forecast (FY)$17.89M
Endovia Health Sciences Inc Business Overview & Revenue Model
Company Description
Endovia Health Sciences is a diversified cannabinoid-based health sciences platform. The company's strategy focuses on three main areas: commercializing differentiated cannabinoid-based pharmaceutical products internationally, advancing cannabinoi...
How the Company Makes Money
Splash Beverage Group primarily makes money by selling packaged beverage products under its brand portfolio into wholesale and retail channels. Revenue is generally generated when products are shipped/sold to distributors, retailers, or other chan...
Endovia Health Sciences Inc Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
7
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Endovia Health Sciences Inc Technical Analysis
Negative
0.42
Price Trends
0.48
Negative
0.78
Negative
1.94
Negative
Market Momentum
-0.02
Negative
43.41
Neutral
23.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDVA, the sentiment is Negative. The current price of 0.42 is above the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.48, and below the 200-day MA of 1.94, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 43.41 is Neutral, neither overbought nor oversold. The STOCH value of 23.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EDVA.
Endovia Health Sciences Inc Risk Analysis
Endovia Health Sciences Inc disclosed 42 risk factors in its most recent earnings report. Endovia Health Sciences Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Endovia Health Sciences Inc Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | $2.33B | 20.57 | 6.96% | 2.49% | 0.56% | -28.00% | |
57 Neutral | $7.86B | -3.65 | -22.65% | 4.64% | -1.77% | -326.16% | |
55 Neutral | $1.95B | -27.33 | -8.89% | ― | -6.06% | -195.51% | |
45 Neutral | $2.68M | -0.02 | 592.71% | ― | -83.63% | 65.38% |
* Consumer Defensive Sector Average
EDVA
Endovia Health Sciences Inc
0.37
-6.60
-94.76%
SAM
Boston Beer
185.56
-36.41
-16.40%
CCU
Compania Cervecerias Unidas SA
12.41
0.33
2.76%
TAP
Molson Coors
42.09
-6.94
-14.15%
YHC
LQR House
1.66
-87.56
-98.14%
IBG
Innovation Beverage Group Ltd.
1.05
-14.20
-93.11%
Endovia Health Sciences Inc Corporate Events
Business Operations and StrategyExecutive/Board Changes
Endovia appoints interim leaders with incentive-focused pay
Positive
Aug 26, 2026
On August 20, 2026, Endovia Health Sciences, Inc. appointed Brady Cobb as interim chief executive officer and Michael Bondurant as interim chief operating officer under new employment agreements that set base salaries of $300,000 and $275,000, res...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Endovia launches FDA-backed CannEpil veterinary pain program
Positive
Aug 25, 2026
On August 25, 2026, Endovia Health Sciences announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has opened Investigational New Animal Drug File No. 14145 for the company’s CannEpil® veterinary pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.